Toronto, Ontario / ACCESSWIRE / September 9, 2014 / Theralase Technologies Inc. (“Theralase”) (TLT.V) (TLTFF: OTC Link(R)) announced today that it has successfully launched its TLC-3000 multi wavelength laser system capable of activating its patented and patent pending Photo Dynamic Compounds (PDCs) for the destruction of cancer in an preclinical environment. This is the first commercial system on the market capable of effectively activating a 96 well plate of cancer cells with wavelengths in the visible to Near Infrared (NIR) spectrum using programmable energy levels. Intellectual protection for this system was recently applied for under a pending US patent.
The new multi wavelength laser system has been delivered to Princess Margaret Cancer Centre, University Health Network (“UHN”) and to the University of Toledo for evaluation of safety and efficacy.
Further developments and enhancements of this multi wavelength laser technology in 2015 will be to activate Theralase’s patented and patent pending PDCs from a few hundred microns (millionths of a meter) to ten centimeters in depth in human applications, allowing oncologists the ability to target surface as well as deep cancerous tumors.
Dr. Arkady Mandel, Chief Scientific Officer of Theralase stated, “This new multi-wavelength laser system combined with Theralase’s cutting-edge PDCs presents the first opportunity for our scientists to quickly and effectively evaluate the safety and efficacy of the PDCs in different cancer cell lines, dramatically increasing throughput. The new laser system is customizable allowing the user to adjust both the wavelength of laser light emitted and the amount of light energy delivered to a specific set of PDC impregnated cancer cells. By optimizing this combination of light and PDC delivered to the cancer cells, our scientists are able to more quickly ascertain which PDC is most effective for a particular type of cancer. This will prove indispensable in the future as Theralase investigates the destruction of additional types of cancer beyond bladder cancer.”
Roger Dumoulin-White, President and CEO of Theralase stated, “Theralase continues to advance our anti-cancer PDC technology both in development and in more comprehensive intellectual protection. This new multi-wavelength laser system is just the latest addition to the new technology we plan to bring to market in the research, development and commercialization of sophisticated medical laser systems used to activate our cancer killing PDCs in a variety of human applications. Our long term strategy is to commercialize the PDC technology, the precision laser systems that activate them and the consumables associated with each treatment to ensure long lasting shareholder value and the best possible treatment for patients inflicted with this terrible disease. The ability to provide personalized Photo Dynamic Therapy (PDT) for cancer patients to destroy their cancer permanently and prevent its recurrence, all in a single treatment remains at the forefront of our minds.”
About Theralase Technologies Inc.
Founded in 1994, Theralase Technologies Inc. (“Theralase”) (TLT.V) (TLTFF: OTC Link(R)) designs, manufactures and markets patented super-pulsed laser technology used for the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing. Theralase has sold over 1200 systems to licensed healthcare practitioners such as: medical doctors, chiropractors, physical therapists and athletic therapists. Theralase has been very successful in healing nerve, muscle and joint conditions in clinical practice and now Theralase’s scientists are investigating the application of its lasers in the destruction of cancer using specially designed molecules called Photo Dynamic Compounds (PDCs) which localize to the DNA of cancer cells and then, when activated by light, destroy the cancer cells.
Additional information is available at www.theralase.com and www.sedar.com .
This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO, Theralase Technologies Inc.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com
SOURCE: Theralase Technologies Inc.